NewAmsterdam Pharma Co N.V. (NAMS) company profile
Close on Nov 17, 2026Market cap $2.32BP/E –Yield –
About NewAmsterdam Pharma
Pharmaceutical Preparations, SIC 2834
This late-stage biopharmaceutical company focuses on developing therapies for cardiometabolic disorders in patient groups with inadequate or poorly tolerated existing treatment options. Its primary candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor investigated as a once-daily monotherapy or in a fixed-dose combination with ezetimibe. These investigational therapies serve as adjuncts to statin regimens to lower low-density lipoprotein cholesterol in individuals at risk of cardiovascular disease, atherosclerotic cardiovascular disease, and heterozygous familial hypercholesterolemia.
The company operates without commercial retail locations or operational store facilities, as its pipeline remains under clinical evaluation. Clinical research programs encompass studies conducted across multiple international regions, including the United States, Europe, Japan, and China, with pivotal trials enrolling thousands of participants globally. Commercialization and licensing rights are established in European countries via a third-party partnership, while United States rights remain retained internally. The text does not state the company's headquarters location.
Summary of the business section of NewAmsterdam Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NewAmsterdam Pharma Co N.V.
- Headquarters
- Narrden, P7
- Address
- Gooimeer 2-35 1411 DC
- Phone
- 35 206 2971
- Website
- newamsterdampharma.com
- Employees
- 100, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- Deloitte Accountants B.V, Eindhoven, The Netherlands
Stock & identifiers
- Ticker
- NAMS
- Other tickers
- NAMSW
- Exchange
- Nasdaq
- IPO date
- Feb 9, 2021
- Shares outstanding
- 120M, Aug 3, 2026
- Public float
- $1.35B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1936258
- FIGI
- BBG01BNNTQN4
- Share class FIGI
- BBG01BNNTQP2
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer, Director | 122,802 |
| Michael H. Davidson | Chief Executive Officer, Director | 1,078,638 |
| Robert William Gunning | Vice President, Controller | 3,200 |
| Louise Frederika Kooij | Chief Accounting Officer | 49,353 |
| Mayur Ian Somaiya | Chief Financial Officer | 98,166 |
| Douglas F. Kling | Chief Operating Officer | 44,000 |
| Michael F. Marino III | See Remarks | 55,000 |
| Juliette Berangere Audet | See Remarks | 15,104 |
| William A. Jones Jr | Chief Commercial Officer | 43,000 |
| John W. Smither | Director | 8,760 |
| Louis G. Lange | Director | 10,806 |
| der Kamp Hilde Johanna van | Director | 10,360 |
| William Lewis | Director | 10,360 |
| Mark C. McKenna | Director | 10,360 |
| Adele M. Gulfo | Director | 14,260 |
| James N. Topper | Director | 6,829,524 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $13.64M | $30.50M | $4.30M | $322 | $135 |
| FY2024 | $6.47M | $49.55M | $2.59M | $236 | $104 |
| FY2023 | $5.81M | $4.72M | $3.27M | $102 | $105 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Michael Davidson, M.D. Chief Executive Officer | $646.15K | $3.57M | $8.93M | $474.92K | $18.07K | $13.64M | +111% |
| Ian Somaiya Chief Financial Officer | $486.72K | $986.48K | $2.94M | $269.67K | $14.00K | $4.70M | +275% |
| Louise Kooij Chief Accounting Officer | $452.22K | $470.80K | $1.07M | $220.46K | $22.75K | $2.24M | – |
| John Kastelein, M.D., Ph.D. FESC Chief Scientific Officer | $537.87K | $1.33M | $2.67M | $270.28K | – | $4.81M | +42% |
| Douglas Kling Chief Operating Officer | $519.97K | $1.31M | $3.34M | $256.08K | $14.00K | $5.44M | +111% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 100 employees, consisting of clinical, research and development, business development, regulatory, finance and operational personnel.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 22, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 22, 2022 | Name change | Name changed from NewAmsterdam Pharma Co B.V. to NewAmsterdam Pharma Co N.V. |
| Nov 18, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 4, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
See a number that looks wrong?